Entact Bio

Entact Bio is a preclinical biotechnology company focused on developing precision medicines that enhance the function of beneficial proteins to address diseases with high unmet medical need. The company utilizes its proprietary end-to-end Encompass platform to design enhancement-targeting chimeric (ENTAC) molecules. These orally available, bifunctional small molecules function as molecular matchmakers, specifically recruiting enzymes known as deubiquitylases (DUBs) to target proteins. By harnessing this natural cellular mechanism to selectively remove or shorten ubiquitin chains, ENTACs can restore protein levels, relocate proteins within the cell, or alter their activity. This approach enables the targeting of previously undruggable pathways, offering a novel therapeutic modality for genetic disorders and complex diseases.

By focusing on enhancing proteins rather than inhibiting or eliminating them, Entact Bio aims to provide new treatment options for patients underserved by current therapies. Founded in 2020 and headquartered in Watertown, Massachusetts, the company is backed by a syndicate of life sciences investors and is led by an experienced management and scientific team. Their efforts are directed toward advancing a pipeline of ENTAC candidates, leveraging a deep integration of biological, chemical, and computational tools to identify targets and optimize target-DUB pairs. The company continues to mature its platform and clinical development capabilities to translate this scientific innovation into impactful medicines for human health.